tetano
Editor, Senior Moderator
SEATTLE--(BUSINESS WIRE)--Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, today announced results from a Phase 2a viral challenge study of TCN-032 for the universal treatment of influenza A. The results of this study represent the first demonstration that a non-neutralizing antibody can provide immediate immunity and potential therapeutic benefit in influenza. TCN-032 is a recombinant, fully human monoclonal antibody that has the potential to treat patients who are hospitalized with serious influenza, as well as during pandemic outbreaks. -
See more at: http://www.businesswire.com/news/rx...eutic-Antibody-Influenza#sthash.9DFkkOzm.dpuf
See more at: http://www.businesswire.com/news/rx...eutic-Antibody-Influenza#sthash.9DFkkOzm.dpuf